newsfilter
← Latest News
GlobeNewswire·

Turning Point Therapeutics Reports Second-Quarter Financial Results, Provides Operational Updates

Phase 1/2 TRIDENT-1 Enrollment Reaches Approximately 300 Patients, Including More than 50 in the ROS1-Positive TKI-naïve NSCLC Cohort (EXP-1) TPX-0022 Granted Fast Track Designation in MET Amplified Advanced or Metastatic Gastric Cancer or Gastroesoph